Publications by authors named "C F van Heyningen"
Article Synopsis
- * A study was conducted with 164 patients showing that those with PCSK9 mutations had higher LDL cholesterol and a significant risk of coronary artery disease compared to others with different mutations.
- * A clinical trial demonstrated that alirocumab significantly reduced LDL cholesterol levels in these patients, showing a 62.5% reduction in just 2 weeks, highlighting its effectiveness and tolerability for managing high cholesterol in PCSK9 mutation carriers.
Objective: Serum cardiac troponins can be elevated in acute coronary syndromes (ACS) and other non-ACS conditions. We investigated the usefulness of a prediction score model comprising clinical variables to distinguish patients with ACS from other non-ACS conditions.
Methods: Two independent, non-randomized observational cohorts (groups 1 and 2) were examined, comprising consecutive patients who were admitted to a university teaching hospital and found to have a raised serum troponin T level (>or=0.